Acorda Therapeutics Inc - ESG Rating & Company Profile powered by AI
The Sustainability assessment for Acorda Therapeutics Inc indicates the company's reporting of the UN SDGs. Complete ESG assessment of Acorda Therapeutics Inc are accessed by signing in. The Disclosure rating includes 17 United Nations Sustainable Development Goals including: 'Gender Equality', 'Responsible Production & Consumption' and 'Life on Land'.
Acorda Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 6.4 and governance score of 8.0.
7.5
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
209 | WuXi AppTec Co Ltd | 7.6 | High |
209 | Waters Corp | 7.6 | High |
256 | Acorda Therapeutics Inc | 7.5 | High |
256 | Alkermes Plc | 7.5 | High |
256 | Athira Pharma Inc | 7.5 | High |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Acorda Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Acorda Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Acorda Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Acorda Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Acorda Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Acorda Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Acorda Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Acorda Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Acorda Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Acorda Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Acorda Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Acorda Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Acorda Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Acorda Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Acorda Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Acorda Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Acorda Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Acorda Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.